AstraZeneca PLC (AZN.L)
AZN.L on London Stock Exchange
5,665.00GBp
12:51pm BST
5,665.00GBp
12:51pm BST
Change (% chg)
46.00 (+0.82%)
46.00 (+0.82%)
Prev Close
5,619.00
5,619.00
Open
5,708.00
5,708.00
Day's High
5,708.00
5,708.00
Day's Low
5,628.00
5,628.00
Volume
502,959
502,959
Avg. Vol
1,806,337
1,806,337
52-wk High
6,126.40
6,126.40
52-wk Low
4,544.50
4,544.50
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Jun '18 | 5,155.00 | 0.276 |
| Mar '18 | 5,178.00 | 0.268 | |
| FY 2017 | Dec '17 | 5,777.00 | 1.048 |
| Sep '17 | 6,232.00 | 0.541 | |
| Jun '17 | 5,051.00 | 0.376 | |
| Mar '17 | 5,405.00 | 0.424 | |
| FY 2016 | Dec '16 | 5,585.00 | 1.455 |
| Sep '16 | 5,699.00 | 0.801 | |
| Jun '16 | 5,603.00 | -0.002 | |
| Mar '16 | 6,115.00 | 0.511 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Dec-18 | 11 | 6,541.28 | 7,294.80 | 5,972.00 | 5,905.44 |
| Quarter Ending Mar-19 | 3 | 5,720.33 | 6,075.00 | 5,493.00 | 5,018.07 |
| Year Ending Dec-18 | 25 | 22,374.00 | 23,199.00 | 21,048.00 | 21,961.90 |
| Year Ending Dec-19 | 27 | 23,835.80 | 25,852.00 | 22,228.00 | 23,564.70 |
| Earnings (per share) | |||||
| Quarter Ending Dec-18 | 10 | 1.24 | 1.72 | 0.90 | 0.93 |
| Quarter Ending Mar-19 | 3 | 0.93 | 0.97 | 0.87 | -- |
| Year Ending Dec-18 | 25 | 3.40 | 3.79 | 3.30 | 3.77 |
| Year Ending Dec-19 | 28 | 3.88 | 4.58 | 3.25 | 4.24 |
| LT Growth Rate (%) | 4 | 8.24 | 12.50 | 3.70 | 3.89 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | 22.12 | 30.95 | 32.69 | |
| P/E High - Last 5 Yrs. | 72.73 | 40.57 | 45.21 | |
| P/E Low - Last 5 Yrs. | 9.58 | 23.31 | 23.82 | |
| Beta | 1.04 | 0.89 | 0.88 | |
| Price to Sales (TTM) | 3.94 | 3.93 | 5.82 | |
| Price to Book (MRQ) | 6.27 | 4.78 | 4.90 | |
| Price to Tangible Book (MRQ) | -- | 5.61 | 6.53 | |
| Price to Cash Flow (TTM) | 13.70 | 22.58 | 22.98 | |
| % Owned Institutions | -- | 1.13 | 2.14 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 1.58 | 1.51 | |
| Dividend Yield - 5 Year Avg | 5.55 | 1.58 | 1.52 | |
| Dividend 5 Year Growth Rate | 4.86 | 4.39 | 5.38 | |
| Payout Ratio(TTM) | 62.12 | 46.24 | 43.96 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -9.85 | 2.19 | 7.73 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -9.65 | 4.58 | 5.32 | |
| Sales - 5 Yr. Growth Rate | -7.29 | 9.69 | 9.89 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | 15,985.23 | 19.82 | 22.57 | |
| EPS (TTM) vs TTM 1 Yr. Ago | 74.09 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -17.55 | 9.96 | 10.95 | |
| Capital Spending - 5 Yr. Growth Rate | 12.28 | 15.12 | 14.94 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | 0.73 | 2.18 | 2.25 |
| Current Ratio (MRQ) | 0.91 | 2.97 | 3.05 |
| LT Debt to Equity (MRQ) | 122.99 | 9.93 | 12.63 |
| Total Debt to Equity (MRQ) | 144.47 | 13.92 | 16.96 |
| Interest Coverage (TTM) | 4.61 | 41.53 | 37.54 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | 82.88 | 55.20 | 54.92 | |
| Gross Margin - 5 Yr. Avg. | 80.69 | 52.31 | 52.45 | |
| EBITD Margin (TTM) | 38.95 | -- | -- | |
| EBITD - 5 Yr. Avg | 31.99 | 18.46 | 11.10 | |
| Operating Margin (TTM) | 24.85 | 14.35 | 4.36 | |
| Operating Margin - 5 Yr. Avg. | 17.97 | 14.35 | 6.45 | |
| Pre-Tax Margin (TTM) | 18.09 | 14.89 | 5.41 | |
| Pre-Tax Margin - 5 Yr. Avg. | 14.67 | 14.80 | 6.89 | |
| Net Profit Margin (TTM) | 17.34 | 11.11 | 1.68 | |
| Net Profit Margin - 5 Yr. Avg. | 12.74 | 11.07 | 3.14 | |
| Effective Tax Rate (TTM) | 4.14 | 23.35 | 23.23 | |
| Effective Tax Rate - 5 Yr. Avg. | 13.16 | 23.58 | 24.11 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 278,767 | 912,999,537 | 812,879,200 | |
| Net Income/Employee (TTM) | 48,342 | 107,437,502 | 95,609,515 | |
| Receivable Turnover (TTM) | 4.36 | 5.63 | 5.78 | |
| Inventory Turnover (TTM) | 1.40 | 2.61 | 3.60 | |
| Asset Turnover (TTM) | 0.34 | 0.95 | 0.92 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | 5.82 | 11.37 | 10.94 | |
| Return on Assets - 5 Yr. Avg. | 5.71 | 12.62 | 12.05 | |
| Return on Investment (TTM) | 7.86 | 14.77 | 14.32 | |
| Return on Investment - 5 Yr. Avg. | 7.89 | 16.45 | 15.66 | |
| Return on Equity (TTM) | 28.47 | 16.27 | 16.04 | |
| Return on Equity - 5 Yr. Avg. | 15.71 | 17.52 | 16.92 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -6.90 | -3.76 | -7.29 |
| EPS (TTM) % | 23.76 | 10.68 | -17.55 |
| Dividend % | 26.80 | 8.24 | 4.86 |
Note: Units in Millions of US Dollars
Performance for AstraZeneca PLC
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | 7.60 | 5.39 | 99 | 23 |
| 13 Week | 0.47 | -2.14 | 99 | 34 |
| 26 Week | 7.52 | 4.45 | 99 | 28 |
| 52 Week | 2.55 | -5.39 | 99 | 12 |
| YTD | 16.15 | 8.98 | 99 | 24 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- UK Stocks-Factors to watch on Oct 16
- UPDATE 5-May says Irish backstop can't derail deadlocked Brexit talks
- AstraZeneca will keep UK investment freeze if no Brexit clarity
- AstraZeneca will keep UK investment freeze if no Brexit clarity
- UPDATE 2-AstraZeneca will keep UK investment freeze if no Brexit clarity
Institutional Holders
| % Shares Owned: | 55.94% |
| # of Holders: | 577 |
| Total Shares Held: | 708,639,676 |
| 3 Mo. Net Change: | 498,394 |
| # New Positions: | 14 |
| # Closed Positions: | 15 |
| # Increased Positions: | 117 |
| # Reduced Positions: | 148 |
| # Net Buyers: | -31 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
- What does AstraZeneca plc's deal with Pfizer mean for shareholders?
- Is Hikma Pharmaceuticals plc the best FTSE 100 healthcare stock to own after today’s update?
- 3 stocks to help you retire early
- Is it time to take profits on GlaxoSmithKline plc and AstraZeneca plc?
- These FTSE 100 stars have exploded in Q3! And they're not finished yet
- Why now is the perfect time to buy these 3 super income stocks